Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $3.2 million.

  • Agios Pharmaceuticals' Amortizatization of Intangibles fell 4309.12% to $3.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $12.4 million, marking a year-over-year decrease of 1422.75%. This contributed to the annual value of $12.4 million for FY2025, which is 1422.75% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Amortizatization of Intangibles stood at $3.2 million for Q4 2025, which was down 4309.12% from $3.1 million recorded in Q3 2025.
  • Agios Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $5.6 million during Q4 2024, with a 5-year trough of $2.2 million in Q3 2023.
  • Its 5-year average for Amortizatization of Intangibles is $2.9 million, with a median of $2.8 million in 2023.
  • In the last 5 years, Agios Pharmaceuticals' Amortizatization of Intangibles surged by 10399.56% in 2024 and then crashed by 4309.12% in 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $2.4 million in 2021, then rose by 6.44% to $2.6 million in 2022, then grew by 7.41% to $2.8 million in 2023, then skyrocketed by 104.0% to $5.6 million in 2024, then crashed by 43.09% to $3.2 million in 2025.
  • Its Amortizatization of Intangibles stands at $3.2 million for Q4 2025, versus $3.1 million for Q3 2025 and $3.1 million for Q2 2025.